Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC

Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn:  .

“I am excited to share a pivotal study published in Nature Medicine titled ‘Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial’. This research explores the combination therapy of botensilimab and balstilimab in treating heavily pre-treated patients with microsatellite stable metastatic colorectal cancer (MSS mCRC).

– Predictive Factor of Response: The site of metastases, specifically liver involvement, was identified as a significant predictive factor for therapy response. Patients without active liver metastases (NLM) demonstrated more favorable outcomes.
– Response Rates: In patients with NLM, the objective response rate (ORR) was 22%, and the disease control rate (DCR) was 73%. Conversely, patients with active liver metastases (LM) had an ORR of 0% and a DCR of 25%.
– Safety Profile: The combination therapy exhibited a manageable safety profile with no new immune-mediated safety signals.

This study underscores the importance of considering the site of metastatic disease in predicting the efficacy of immune checkpoint blockade (ICB) therapies. The findings suggest that patients with MSS mCRC without active liver metastases may benefit more from the combination of botensilimab and balstilimab.

The results offer new hope for patients with MSS mCRC, a group that has historically shown poor response to ICB. The identification of liver metastases as a predictive factor could guide more personalized and effective treatment strategies.”

Source: Victor Moreno/LinkedIn